Abstract
Aims/hypothesisIndividuals with type 2 diabetes are heterogeneous in their glycaemic control as tracked by blood HbA1c levels. Here, we investigated the extent to which gene expression levels in blood reflect current and future HbA1c levels.MethodsHbA1c levels at baseline and 1 and 2 year follow-up were compared with gene expression levels in 391 individuals with type 2 diabetes from the Hoorn Diabetes Care System Cohort (15,564 genes, RNA sequencing). The functions of associated baseline genes were investigated further using pathway enrichment analysis. Using publicly available data, we investigated whether the genes identified are also associated with HbA1c in the target tissues, muscle and pancreas.ResultsAt baseline, 220 genes (1.4%) were associated with baseline HbA1c. Identified genes were enriched for cell cycle and complement system activation pathways. The association of 15 genes extended to the target tissues, muscle (n = 113) and pancreatic islets (n = 115). At follow-up, expression of 25 genes (0.16%) associated with 1 year HbA1c and nine genes (0.06%) with 2 year HbA1c. Five genes overlapped across all time points, and 18 additional genes between baseline and 1 year follow-up. After adjustment for baseline HbA1c, the number of significant genes at 1 and 2 years markedly decreased, suggesting that gene expression levels in whole blood reflect the current glycaemic state and but not necessarily the future glycaemic state.Conclusions/interpretationHbA1c levels in individuals with type 2 diabetes are associated with expression levels of genes that link to the cell cycle and complement system activation.
Highlights
Individuals with type 2 diabetes are heterogeneous in their disease trajectory, glycaemic control over time [1], response to therapy and in the disease-related complications they develop, including micro- and macrovascular complications [2]
Conclusions/interpretation HbA1c levels in individuals with type 2 diabetes are associated with expression levels of genes that link to the cell cycle and complement system activation
We have investigated the relationship between blood gene expression levels and HbA1c levels in almost 400 individuals with type 2 diabetes selected from the Hoorn Diabetes Care System (DCS) cohort [16]
Summary
Individuals with type 2 diabetes are heterogeneous in their disease trajectory, glycaemic control over time [1], response to therapy and in the disease-related complications they develop, including micro- and macrovascular complications [2]. Individuals with type 2 diabetes would benefit from new markers for future glycaemic control, especially when in an early stage of the disease. Accelerated by recent technological advances, other molecular variables, such as epigenetic modifications and gene expression, are increasingly being investigated in relation to blood glucose and type 2 diabetes and its progression. DNA methylation near known type 2 diabetes loci (for example, KLF14, ZNF518B, INS) is associated with measures of glucose homeostasis (HbA1c, 2 h insulin) in healthy individuals [6, 7]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.